THRESHOLD PHARMACEUTICALS, INC. (NASDAQ:THLD) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial
Condition
On May 15, 2017, Threshold Pharmaceuticals, Inc. issued a press
release regarding its financial results for the first quarter
ended March 31, 2017. A copy of the press release is furnished as
Exhibit 99.1 to this Current Report and is incorporated herein by
reference. The press release contains statements intended as
forward-looking statements which are subject to the cautionary
statements about forward-looking statements set forth therein.
The information furnished to this Item 2.02 (including Exhibit
99.1 hereto) shall not be deemed filed for the purposes of
Section 18 of the Securities Exchange Act of 1934, as amended, or
the Exchange Act, or otherwise subject to the liabilities of that
Section or Sections 11 and 12(a)(2) of the Securities Act of
1933, as amended, or the Securities Act. The information
contained herein and in the accompanying exhibit shall not be
deemed to be incorporated by reference into any filing under the
Securities Act or the Exchange Act, whether made before or after
the date hereof, regardless of any general incorporation language
in such filing.
Item 9.01. Financial Statements and Exhibits
Exhibits
| Exhibit Number | Description | |
| 99.1 |
Press Release of Threshold Pharmaceuticals, Inc. dated May 15, 2017 regarding its financial results for the first quarter ended March 31, 2017. |
About THRESHOLD PHARMACEUTICALS, INC. (NASDAQ:THLD)
Threshold Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of therapeutic and diagnostic agents that selectively target tumor cells for the treatment of patients living with cancer. It is developing two therapeutic product candidates based on hypoxia-activated prodrug technology: evofosfamide and tarloxotinib. Evofosfamide is designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not in healthy tissues. Tarloxotinib is under investigation in two Phase II proof-of-concept trials: one for the treatment of patients with mutant EGFR-positive, T790M-negative advanced NSCLC progressing on an EGFR TKI, and the other for patients with recurrent or metastatic squamous cell carcinomas of the head and neck. [18F]-HX4 is an investigational Positron Emission Tomography imaging agent for hypoxia to identify and quantify the degree of hypoxia in tumors in vivo. THRESHOLD PHARMACEUTICALS, INC. (NASDAQ:THLD) Recent Trading Information
THRESHOLD PHARMACEUTICALS, INC. (NASDAQ:THLD) closed its last trading session up +0.004 at 0.500 with 165,264 shares trading hands.
